Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-27

Study Completion Date

2024-05-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an imaging study designed to illuminate the function of the cholinergic system and its association with cognitive skills in people with Parkinson's disease. The hypothesis of this study is that there will be an association between cholinergic terminal density, sex hormones, and cognitive functioning. Participants will receive a PET and MRI scan along with a battery of neurocognitive tests at baseline and again at 18 months follow-up. Hormone levels will be measured at baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109

Parkinson Disease Alzheimer Disease

COMPLETED PHASE1

Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease

NCT01106976

Parkinson's Disease

COMPLETED

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675

Parkinsonian Syndrome

COMPLETED PHASE2

Cholinergic Nicotinic Receptors and Cognition in PD

NCT02076295

Parkinson's Disease

COMPLETED

Innovative Biomarkers in de Novo Parkinson's Disease

NCT03940677

Parkinson's Disease Healthy Controls Group - Age and Sex-matched

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an imaging study designed to illuminate the functioning of the cholinergic system in people with Parkinson's disease. Some people with Parkinson's disease develop trouble with certain aspects of thinking such as memory. Studies have shown an association between a decline in thinking skills and dysfunction of the cholinergic system. This study will use the novel PET tracer \[18F\]VAT to provide more specific information about how the cholinergic system works by enabling direct measurement of cholinergic terminal density and projections. The hypothesis of this study is that there will be an association between cholinergic terminal density, sex hormones, and cognitive functioning. This is a longitudinal observational study that involves a screening visit and four study visits over the course of 18 months. The visits consist of neurocognitive assessments and imaging (MRI and PET scans) administered at baseline and at 18 months follow-up. Hormone levels will also be measured at baseline. This study is open to people with Parkinson's disease who have either normal cognition or mild cognitive impairment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 50-80
* Diagnosis of Parkinson's disease
* Ability to provide informed consent
* Ability to speak English
* Normal cognition or mild cognitive impairment
* Willingness to go off parkinsonian medication for 12 hours prior to two of the study visits

Exclusion Criteria

* Contraindication for MRI
* Abnormal clinical brain MRI, specifically with evidence of large-vessel stroke or mass lesion
* History of stereotactic or ablative brain surgery
* Pregnancy
* Recent participation in other research studies involving radiation such that the annual research radiation dose would exceed FDA Limit if participating in this study
* Prior brain injury (eg., TBI)
* Baseline cognitive impairment due to genetic or developmental disorder
* Active illicit drug use or alcohol abuse
* Incapable of staying still for a 2-hour PET or MRI study
* Use of CNS-penetrating medications affecting the cholinergic system, including cholinesterase inhibitors and anticholinergics, up to 60 days prior to study participation

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No